Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.42 |
| ▸ | CCNK | O75909 | 3/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22554174 | 0.88 | NUDT1 (0.43) | NUDT1CCNKCDK12HTR1AGABRA1 | |
| SCHEMBL30731058 | 0.83 | NUDT1 (0.42) | NUDT1CCNKCDK12HTR1AGABRA1 | |
| SCHEMBL22570933 | 0.83 | NUDT1 (0.42) | NUDT1CCNKCDK12HTR1AGABRA1 | |
| SCHEMBL22554070 | 0.81 | DAO (0.44) | DAONUDT1CCNKCDK12 | |
| SCHEMBL30731002 | 0.81 | DAO (0.44) | DAONUDT1CCNKCDK12 | |
| SCHEMBL22554207 | 0.77 | NAMPT (0.45) | NUDT1CCNKCDK12 | |
| SCHEMBL30731054 | 0.74 | ABL1 (0.44) | DAONUDT1 | |
| SCHEMBL22554309 | 0.74 | ABL1 (0.44) | DAONUDT1 | |
| SCHEMBL3416746 | 0.74 | PRKCI (0.40) | DAONUDT1CCNKCDK12GABRA1 | |
| SCHEMBL30731078 | 0.73 | NUDT1 (0.48) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-112088157-A | Aryl-bipyridine amine derivatives as phosphoinositide kinase inhibitors | 拉文纳制药公司 | 2020-12-15 | — | — | CN | disclosed |
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PIP5K1C | DAO 3277/4885NUDT1 2148/4885EGLN2 4173/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | DAO 3277/4885NUDT1 2148/4885EGLN2 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.